Status and phase
Conditions
Treatments
About
This one-year study is designed to investigate the safety and efficacy of TPX-100, a 23-amino acid chondrogenic peptide, delivered by intra-articular injection, in regeneration of knee cartilage in subjects with bilateral osteoarthritis of the knee.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 25 and ≤ 75
Patello-femoral osteoarthritis of both knees of mild to moderate severity with intact meniscus and ligamentous stability (cruciate and collateral ligaments)
Able to read, understand, sign and date the subject informed consent
Willingness to use only acetaminophen as the primary analgesic (pain-relieving) study medication. The maximum dose of acetaminophen must not exceed 4 grams/day (4000 mg per day).
Willingness to use only hydrocodone/acetaminophen for breakthrough pain during the injection period (through study day 30).
Willingness not to use non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen for the first 30 days of the study.
Female subjects of child bearing potential who are sexually active (non-abstinent) must agree to and comply with using 2 highly effective methods of birth control (oral contraceptive, implant, injectable or indwelling intrauterine device, condom with spermicide, or sexual abstinence) while participating in the study.
Exclusion criteria
Contraindication to MRI, including: metallic fragments, clips or devices in the brain, eye, or spinal canal; implanted devices that are magnetically programmed; weight > 300 lbs.; moderate or severe claustrophobia; previous intolerance of MRI procedure
ICRS grade greater than Grade 3, or Grade 4 focal defects greater than 1 cm, as confirmed by centrally-read screening MRI
MRI evidence of inflammatory or hypertrophic synovitis
Prior surgery in the knees, excluding procedures for debridement only (no microfracture)
Joint replacement or any other knee surgery planned in the next 12 months
History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or infectious cause for arthritis
Knee effusion >2+ on the following clinical scale:
Last viscosupplementation (e.g. Synvisc® or similar hyaluronic acid product) injected into either knee < 3 months before screening
Last intra-articular knee injection of corticosteroids < 2 months before screening
Use of any steroids (except inhaled corticosteroids for respiratory problems) during the previous month before screening
Known hypersensitivity to TPX-100
Known hypersensitivity to acetaminophen or hydrocodone
History of arthroscopy in either knee in the last 3 months before screening
History of septic arthritis, gout or pseudo-gout, of either knee in previous year before screening
Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms consistent with meniscal tear)
Patellar chondrocalcinosis on X-Ray
Skin problem, rash or hypersensitivity, affecting either knee at the injection site
Bleeding problem, platelet or coagulation deficiency contraindicating, in the doctor's opinion, any intra-articular injection
Active systemic infection
Current treatment or treatment within the previous 2 years prior to the Screening Visit for any malignancy except basal cell or squamous cell carcinoma of the skin, unless with specific written permission is provided by the Sponsor's medical monitor
Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period
Participation in other clinical osteoarthritis drug studies within one year prior to screening
Currently taking Paclitaxel (mitotic inhibitor), and or Natalizumab (anti-integrin monoclonal antibody).
History of significant liver disease or consumption of more than 3 alcoholic drinks a day. (Definition of one alcoholic drink: 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor such as gin, rum, vodka, or whiskey).
Primary purpose
Allocation
Interventional model
Masking
120 participants in 5 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal